National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Ne...
December 13 2018 - 4:01PM
Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused
on the development and commercialization of new and innovative
treatment options for patients in pain, today announced that TRV734
data were featured in a presentation at the 57th Annual Meeting of
the American College of Neuropsychopharmacology as part of
Trevena’s ongoing collaboration with the National Institute on Drug
Abuse (NIDA).
The presentation, entitled “Modeling Opioid Maintenance Therapy
in Rats: Effects of Chronic Buprenorphine and the Biased Mu-Opioid
Receptor Agonist TRV130 on Relapse to Oxycodone Seeking,” was
delivered by Yavin Shaham, Ph.D., Chief, Behavioral Neuroscience
Research Branch, Intramural Research Program at NIDA. The
presentation included data on Trevena compounds TRV130 and TRV734,
and highlighted data showing that TRV734 reduced drug-seeking
behavior in a rat model of relapse. These data suggest that
TRV734 may be a novel, oral maintenance treatment for addiction to
opioids or heroin.
“Current therapies, such as methadone and buprenorphine, for
patients with opioid abuse disorder have limited or no efficacy for
some patients and are associated with substantial safety and
tolerability concerns,” said Mark A. Demitrack, M.D., Sr. Vice
President and Chief Medical Officer at Trevena. “We are encouraged
by the data generated thus far and are pleased to continue our
collaboration with NIDA to further investigate the potential use of
TRV734 for this important unmet medical need.”
Preclinical studies performed by NIDA scientists suggest that
biased mu opioid receptor ligands, like TRV734, may offer an
alternative to current opioid maintenance therapies.
About TRV734TRV734 is a new chemical entity
(NCE) targeting the same novel mechanism of action as Trevena’s
intravenous (IV) NCE, oliceridine, which selectively stimulates
G-protein coupling at the mu-opioid receptor with low beta-arrestin
recruitment. TRV734 was designed to be orally available, and its
mechanism of action suggests it may offer valuable benefits for two
distinct areas of important unmet medical need: acute and chronic
pain, and management of opioid dependence associated with opioid
use disorder. Trevena is collaborating with NIDA to further
evaluate TRV734 for the management of opioid dependence. TRV734 and
oliceridine are investigational products not approved by FDA for
distribution in the US.
About Trevena Trevena, Inc. is a
biopharmaceutical company focused on the development and
commercialization of new and innovative treatment options for
patients in pain. The Company has three novel and differentiated
drug candidates, including IV oliceridine, for the management of
moderate to severe acute pain in hospitals, TRV250 for the
treatment of acute migraine, and TRV734 for pain and/or management
of opioid dependence. In its preclinical programs, Trevena is
evaluating a set of novel S1P modulators that may offer a new,
non-opiate approach to managing chronic pain.
Cautionary note on forward looking statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company’s strategy, future operations, clinical development of its
therapeutic candidates, plans for potential future product
candidates and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “suggest,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
status, timing, costs, results and interpretation of the Company’s
clinical trials or any future trials, including the data presented
by NIDA with respect to TRV734 that showed TRV734 reduced
drug-seeking behavior in a rat model of relapse and therefore
whether TRV734 may be a novel, alternative maintenance treatment
for addiction to prescription opioids and heroin and may meet an
important unmet need for patients; expectations for regulatory
interactions, submissions, or approvals; availability of funding
sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements;
uncertainties related to the Company’s intellectual property; other
matters that could affect the availability or commercial potential
of the Company’s therapeutic candidates; and other factors
discussed in the Risk Factors set forth in the Company’s Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q filed with
the Securities and Exchange Commission (SEC) and in other filings
the Company makes with the SEC from time to time. In addition, the
forward-looking statements included in this press release represent
the Company’s views only as of the date hereof. The Company
anticipates that subsequent events and developments may cause the
Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so, except
as may be required by law.
This press release, information, and interpretation of the data
is not sanctioned by the American College of
Neuropsychopharmacology.
ContactsTrevena, Inc.
Investors:Erin ClarkSenior Director, Corporate
Strategy & Investor Relations610-354-8840
x355ir@trevena.com
or
Media:pr@trevena.com
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2023 to Apr 2024